Emavusertib (mesylate)

CAT: 0804-HY-135317DSize: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-135317DSize:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Emavusertib mesylate (CA-4948 mesylate) is the mesylate salt form of Emavusertib (HY-135317) . Emavusertib mesylate is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib mesylate inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib mesylate exhibits antitumor activity in mouse model[1][2][3].
CAS Number
[2376399-40-3]
Product Name Alternative
CA-4948 (mesylate)
UNSPSC
12352005
Target
Apoptosis; FLT3; IRAK; MyD88; NF-κB
Related Pathways
Apoptosis; Immunology/Inflammation; NF-κB; Protein Tyrosine Kinase/RTK
Field of Research
Cancer; Inflammation/Immunology
Smiles
CS(=O)(O)=O.O=C(C1=COC(C2=CC=NC(C)=C2)=N1)NC3=C(N4CC[C@H](C4)O)N=C5C(OC(N6CCOCC6)=N5)=C3
Molecular Formula
C25H29N7O8S
Molecular Weight
587.60
References & Citations
[1]Wiese MD, et al. Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2020 Apr 17:1-8.|[2]Guidetti F, et al. Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors. J Clin Med. 2023 Jan 4;12 (2) :399. |[3]Parrondo RD, et al. IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies. Front Immunol. 2023 Oct 26;14:1239082.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2

Popular Products